IPR

Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research

Retrieved on: 
月曜日, 6月 3, 2024
Research, Technology, Medical Devices, Engineering, Dental, Health Technology, Manufacturing, Electronic Design Automation, Health, Science, IPR, Aesthetics, Dental care, University of Insubria, Patient, Dentistry, University, Hospital, Publication, International Medical University, Dentition, Align Technology, Incisor, Probiotic, Medical device

“Align is delighted to announce the awards for research that leads to insights and evidence that advance the applicability of treatment for patients of all ages.

Key Points: 
  • “Align is delighted to announce the awards for research that leads to insights and evidence that advance the applicability of treatment for patients of all ages.
  • We are pleased to support university research around the world in the orthodontic and dental fields,” said Dr. Mitra Derakhshan, Align executive vice president, chief clinical officer, global treatment planning and clinical services.
  • “The publications and lectures resulting from these research endeavors advance the science of dentistry and aim to improve the dental care of the global community.
  • The final recipients were then determined by Align Technology.

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Retrieved on: 
水曜日, 5月 29, 2024
Patient, Learning, Information technology, IPR, Endocrinology, Patent, Calendar, FDA, Teprotumumab, Neonatal Fc receptor, Graves' ophthalmopathy, Autoimmune disease, TED, CIDP, Research, Common stock, Neurology, Hearing loss, Growth factor, Fibroblast growth factor receptor, Pharmaceutical industry

Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2024:

Key Points: 
  • Financial Highlights for Fiscal Fourth Quarter Ended March 31, 2024:
    Cash Position: As of March 31, 2024, Immunovant’s cash and cash equivalents totaled approximately $635 million.
  • Financial Highlights for Fiscal Year Ended March 31, 2024:
    R&D Expenses: Research and development expenses were $212.9 million for the fiscal year ended March 31, 2024, compared to $160.3 million for the fiscal year ended March 31, 2023.
  • G&A Expenses: General and administrative expenses were $57.3 million for the fiscal year ended March 31, 2024, compared to $48.0 million for the fiscal year ended March 31, 2023.
  • Net loss for the fiscal year ended March 31, 2024 and 2023 included $41.1 million and $32.3 million, respectively, related to non-cash stock-based compensation expense.

Vicor patents asserted against infringing NBMs withstand validity challenges

Retrieved on: 
火曜日, 5月 28, 2024
Inter partes review, IPR, Patent, Delta Electronics, PTAB, NBM, IP, ITC, Foxconn, Attention, TPU, Artificial intelligence, District court, VICR, GPU

On July 13, 2023, Vicor filed a complaint at the ITC against Delta alleging infringement of three Vicor patents: U.S. Patent Nos.

Key Points: 
  • On July 13, 2023, Vicor filed a complaint at the ITC against Delta alleging infringement of three Vicor patents: U.S. Patent Nos.
  • 9,166,481 (the “‘481 patent”); 9,516,761 (the “‘761 patent”) and 10,199,950 (the “’950 patent”) (“the asserted patents”).
  • Copycat Non-isolated Bus Converter Modules (“NBMs”), manufactured by infringing competitors, practice the asserted patents.
  • Chief Executive Officer, Dr. Patrizio Vinciarelli, stated: “PTAB decisions, denying all of Delta’s IPRs, debunk expert opinions proffered in Delta’s ill-conceived, failed attempts to invalidate Vicor patents.

The EBA has identified new types of payment fraud and proposes measures to mitigate underlying risks and protect consumers from resultant losses 

Retrieved on: 
火曜日, 5月 28, 2024
IPR, Council, Strong customer authentication, Commission, SCA, PSR, European Parliament, European, Fraud, PSD3, Opinion, PSD2, EBA

The European Banking Authority (EBA) published today an Opinion, in which it assesses payment fraud data that has recently become available to the EBA, identifies new types and patterns of payment fraud, and develops proposals to mitigate them. This Opinion aims at further strengthening the forthcoming legislative framework under the Third Payment Services Directive (PSD3) and Payment Services Regulation (PSR), as it will enshrine anti-fraud requirements for several years to come and needs to be as future-proof as possible.

Key Points: 
  • The EBA has identified new types of payment fraud and proposes measures to mitigate underlying risks and protect consumers from resultant losses
    The European Banking Authority (EBA) published today an Opinion, in which it assesses payment fraud data that has recently become available to the EBA, identifies new types and patterns of payment fraud, and develops proposals to mitigate them.
  • This Opinion aims at further strengthening the forthcoming legislative framework under the Third Payment Services Directive (PSD3) and Payment Services Regulation (PSR), as it will enshrine anti-fraud requirements for several years to come and needs to be as future-proof as possible.
  • However, fraudsters have adapted their techniques and are using more complex types of fraud, such as those based on what is commonly referred to as ‘social engineering’.
  • Documents
    Press contacts
    Franca Rosa Congiu

Travere Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
月曜日, 5月 6, 2024
FDA, Total, Risk, Ligand Pharmaceuticals, European Commission, Research, UPCR, Webcast, HCU, IND, EGFR, PDUFA, SIMD, Civil service commission, Diagnosis, PMDA, GAAP, CMA, Congress, Table, PROTECT, Priority review, Food, Abstract, FSGS, Income tax, CSL Vifor, Quarter, Medication, Therapy, SAN, Plasma, Urine, International, Safety, Proteinuria, ANNA, Immunoglobulin A, Homocysteine, Investigational New Drug, Society, Shanda, New Drug Application, Genetic, European, Disease, Patient, Quality of life (healthcare), IPR, Bank statement, Growth, Pharmaceutical industry

Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.

Key Points: 
  • Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.
  • Travere Therapeutics will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET to discuss company updates as well as first quarter 2024 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.

WWPR WELCOMES RETURNING MEMBERS TO 2024 - 2025 ADVISORY COUNCIL

Retrieved on: 
金曜日, 5月 3, 2024
Wells Fargo, Virginia University, WWPR, Teaching, Life, Growth, Journalism, American University, Georgetown University, Leadership studies, POLITICO, Woman, Delhi University, Economics, Axios, Empowerment, The Washington Post, The New York Times, Elon University, Inside Philanthropy, Committee, WVU, Communication, Emory University, Corporate communication, Advisory Council, West Virginia University, Health communication, Woman of the Year, George Washington University, Minerva, Health, Female, Chicago Sun-Times, Psychology, Capital One, Marketing, Society, DARPA, Partnership, Sociology, Science, Introduction, Master, IPR, Capital city, Bloomberg, Turner, Nursing

WASHINGTON, May 3, 2024 /PRNewswire/ -- Washington Women in Public Relations (WWPR), a leading resource for female communications professionals in the nation's capital, today announces its 2024 - 2025 Advisory Council, a group that provides WWPR's leadership with strategic advice on the direction of the organization.

Key Points: 
  • WASHINGTON, May 3, 2024 /PRNewswire/ -- Washington Women in Public Relations (WWPR), a leading resource for female communications professionals in the nation's capital, today announces its 2024 - 2025 Advisory Council, a group that provides WWPR's leadership with strategic advice on the direction of the organization.
  • The Advisory Council is comprised of local female leaders in the communications and public relations industry.
  • This year, WWPR is pleased to welcome back the 2022 - 2023 Advisory Council members – Susan Matthews Apgood, Sukhi Sahni, Hillarie Turner and Danielle Veira – for another two-year term.
  • "We are thrilled to welcome back our esteemed Advisory Council members, a group of amazing industry veterans with a multitude of experience," said Chelsea Echavarria, WWPR President.

CBP, Canon Announce Partnership Against Counterfeit Products

Retrieved on: 
火曜日, 4月 23, 2024
Safety, Woman, General counsel, Health, Commerce, Intellectual property, Partnership, CBP, IPR, Patent, 3D printing

MELVILLE, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc. (Canon), a leader in digital imaging solutions and U.S. Customs and Border Protection (CBP) announced today a new partnership to help prevent counterfeit products from entering the United States.

Key Points: 
  • MELVILLE, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc. (Canon), a leader in digital imaging solutions and U.S. Customs and Border Protection (CBP) announced today a new partnership to help prevent counterfeit products from entering the United States.
  • Under this partnership, which is part of CBP’s Donations Acceptance Program , Canon will donate 328 verification tools to CBP cargo and mail facilities to aid in authenticating a variety of Canon merchandise.
  • CBP’s enforcement efforts are strengthened by stakeholder collaboration and innovative approaches such as the CBP and Canon partnership.
  • This newest donation with Canon will facilitate the identification and removal of counterfeit goods from the U.S. stream of commerce.

Glaukos Announces First Quarter 2024 Financial Results

Retrieved on: 
水曜日, 5月 1, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Medical Devices, Research, Surgery, Science, GAAP, Investment, Corporation, Conference, Webcast, GKOS, Patient, IPR, EPS, Standard of care, Glaucoma, Retina

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024.
  • “Our record first quarter results reflect successful global execution of our key strategic plans,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • Loss from operations in the first quarter of 2024 was $39.1 million, compared to operating loss of $33.0 million in the first quarter of 2023.
  • Non-GAAP loss from operations in the first quarter of 2024 was $32.8 million, compared to non-GAAP operating loss of $26.8 million in the first quarter of 2023.

Gilead Sciences Announces First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 4月 25, 2024
Oncology, Health, Infectious Diseases, Hospitals, Other Health, Pharmaceutical, Biotechnology, Liver disease, FTC, John Hodgman, Remdesivir, Science, Tax rate, Acute lymphoblastic leukemia, Research, ETR, European, Axicabtagene ciloleucel, Acquisition, IPR, EPS, Research and development, HCV, HIV, Therapy, COVID-19, Growth, B-cell lymphoma, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
  • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter 2024, compared to $0.80 in the same period in 2023.
  • Non-GAAP diluted (loss) EPS was $(1.32) in the first quarter 2024, compared to $1.37 in the same period in 2023.
  • During the first quarter 2024, Gilead paid dividends of $990 million and repurchased $400 million of common stock.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors

Retrieved on: 
金曜日, 4月 12, 2024
Class Action Lawsuit, Professional Services, Legal, ABBV, News, AbbVie, Research, GPM, IPR, GAAP, Person

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) investors concerning the Company’s possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV ) investors concerning the Company’s possible violations of the federal securities laws.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On April 4, 2024, AbbVie disclosed that its prior financial guidance excluded the impact of acquired In-Process Research and Development (“IPR&D”) and milestone expense.
  • Whistleblower Notice: Persons with non-public information regarding AbbVie should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.